Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to estimate the maximum tolerated dose of gefitinib in
combination with fixed dose of irinotecan and vincristine in patients with refractory solid
tumors.